GT Biopharma Inc

General ticker "GTBP" information:

  • Sector: Health Care
  • Industry: Biotechnology
  • Capitalization: $5.9M

GT Biopharma Inc does not follow the US Stock Market performance with the rate: -33.7%.

Estimated limits based on current volatility of 21.8%: low 1.96$, high 3.04$

Factors to consider:

  • Current price 31.8% below estimated low
  • Earnings for 6 months up through Q2 are below our estimates

Stock Forecast*

* forecast is subjective and experimental, should not be used for any investment decisions

Long term estimates were made for the period from 2023-12-31 to 2025-12-30

  • 2023-12-31 to 2024-12-30 estimated range: [4.12$, 12.65$]
  • 2024-12-30 to 2025-12-30 estimated range: [3.80$, 11.12$]

Financial Metrics affecting the GTBP estimates:

  • Negative: Non-GAAP EPS, $ of -12.31 <= 0.10
  • Negative: Operating profit margin, % of -100 <= 1.03
  • Negative: negative Net income
  • Negative: Operating cash flow per share per price, % of -48.02 <= 2.35
  • Positive: Interest expense per share, $ of 0 <= 0
  • Positive: Industry inventory ratio change (median), % of 0 <= 0
  • Negative: Industry operating cash flow per share per price (median), % of -23.87 <= 3.85

Similar symbols

Short-term GTBP quotes

Long-term GTBP plot with estimates

Financial data

YTD 2021-12-31 2022-12-31 2023-12-31
Operating Revenue $0.00MM $0.00MM $0.00MM
Operating Expenses $57.52MM $21.26MM $13.58MM
Operating Income $-57.52MM $-21.26MM $-13.58MM
Non-Operating Income $-0.50MM $0.37MM $5.98MM
Interest Expense $0.72MM $0.01MM $0.00MM
R&D Expense $9.59MM $8.81MM $6.47MM
Income(Loss) $-58.01MM $-20.88MM $-7.60MM
Profit(Loss) $-58.01MM $-20.88MM $-7.60MM
Stockholders Equity $21.91MM $11.73MM $7.48MM
Assets $32.17MM $16.74MM $14.11MM
Operating Cash Flow $-15.61MM $-15.22MM $-8.85MM
Investing Cash Flow $-23.04MM $12.14MM $-2.01MM
Financing Cash Flow $42.32MM $-0.22MM $6.27MM
Earnings Per Share* $-62.54 $-19.30 $-5.64

* EPS are Split Adjusted, recent splits may be reflected with a delay.